RxDoctor Payments Data

Mark Lesher, MD

Ophthalmology · Albuquerque, NMNPI 1376533240

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.2% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Alcon at 43.0% of the total.

$1,475in general payments, 2019–2025

Across 35 payments — averaging $42.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$634
  • Johnson & Johnson Surgical Vision, Inc.$326
  • Bausch & Lomb Americas Inc.$241
  • Tearlab Corp$115
  • Rxsight Inc$110
  • Carl Zeiss Meditec, Inc.$26
  • plus $23 from 1 others
$540in research payments, 2019–2025

Across 1 payment — averaging $540.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Surgical Vision, Inc.$540

What the payments were for

  • Food & beverage$1,34591%
  • Other$1309%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,475 in reported general payments places this provider in the 55th percentile of 81 ophthalmology providers in New Mexico.

See all ophthalmology providers in New Mexico

Medicare billing

Part B allowed, 2024
$433,516
Medicare patients
865
Services billed
2,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate1,639$69,995
MoxifloxacinMoxifloxacin Hcl823$16,492
Ofloxacin752$9,861
Diclofenac Sodium111$1,541
Ketorolac Tromethamine17$800
ErythromycinErythromycin Base31$425
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha31$418
Latanoprost17$218
Tobramycin17$123

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →